Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is among the many Finest Get Wealthy Quick Shares to Purchase Proper Now. As of December 24, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a consensus purchase from all eleven analysts masking the inventory. Whereas the goal worth ranges from $12 to $30, the median worth goal of $19 interprets to an upside potential of 79.92%.
On December 18, Raymond James initiated protection on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with a ‘Robust Purchase’ score and a worth goal of $25, citing stable outcomes from two Section 1/2 scientific trials and inspiring suggestions from the FDA. With that mentioned, the corporate’s lead candidate, LX2006, an AAV gene remedy for cardiomyopathy related to Friedreich’s Ataxia, is “well-positioned for fulfillment” in its pivotal trial, the analyst asserted.
Picture by Nationwide Most cancers Institute on Unsplash
Raymond James expects the inventory to realize momentum in 2026 following a finalized pivotal protocol with the FDA and preliminary proof of idea information on LX2020, an unmodeled gene remedy asset. The agency anticipates LX2006 income of $14.1 million in FY27, going as excessive as $805.3 million in FY32.
Earlier on December 10, Cantor Fitzgerald reaffirmed an ‘Obese’ score on Lexeo Therapeutics, Inc. (NASDAQ:LXEO), with a worth goal of $19. The reaffirmation, implying an upside potential of round 80%, is pushed by the prospects of the corporate’s PKP2-ACM program. The analyst highlighted that the market stays centered on Lexeo’s Friedreich’s ataxia program and the PKP2-ACM program seems “beneath the radar,” notably because the upcoming information anticipated within the subsequent month may shift market notion.
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a New York-based clinical-stage genetic medication firm. Based in 2017, the corporate has a pipeline of packages, together with LX2006, LX2020, and LX2021.
Whereas we acknowledge the potential of LXEO as an funding, we consider sure AI shares supply better upside potential and carry much less draw back threat. For those who’re in search of a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.
READ NEXT: The Finest and Worst Dow Shares for the Subsequent 12 Months and 10 Unstoppable Shares That Might Double Your Cash.
Disclosure: None.